1201902-80-8 Usage
Uses
Used in Oncology:
MLN9708 is used as a proteasome inhibitor for the treatment of multiple myeloma in patients who have received at least one prior therapy. It targets the protein proteasome subunit β type-5, which plays a crucial role in the survival and proliferation of cancer cells. By inhibiting this subunit, MLN9708 helps in controlling the growth of multiple myeloma cells and improving the overall prognosis for patients.
Used in Combination Therapy:
MLN9708 is used in combination with lenalidomide and dexamethasone to enhance the therapeutic effects against multiple myeloma. This combination therapy approach allows for a more effective treatment strategy, as it targets multiple pathways involved in the growth and survival of cancer cells, leading to better patient outcomes.
Used in Drug Development:
As a novel proteasome inhibitor, MLN9708 serves as a valuable compound in the development of new cancer treatments. Its unique mechanism of action and proven efficacy in treating multiple myeloma make it a promising candidate for further research and development in oncology. Additionally, the study of MLN9708's properties and interactions with other drugs can provide insights into the development of other proteasome inhibitors and combination therapies for various types of cancer.
Clinical Use
Highly selective and reversible proteasome inhibitor:
Treatment of multiple myeloma in combination with
lenalidomide and dexamethasone
Synthesis
The structure of ixazomib citrate is particularly interesting in
that it is one of the relatively few marketed drugs which feature
a boron atom within its structure (others of note being the
oncology medication bortezomib and the antifungal drug
tavaborole13). The ostensible scale synthetic approach began
with reaction of commercial 2,5-dichlorobenzoyl chloride (188) with glycine in aqueous NaOH to furnish amide
189 in 97% yield as a white crystalline solid. Acid 189 was then
coupled with commercially available 1,3,2-benzodioxaborolane
190 in the presence of TBTU and DIPEA in DMF at low
temperature to give diamide 191, which was used without
purification for the next step. Borane 191 was then deprotected
with (2-methylpropyl)boronic acid in methanolic HCl to
provide trimer 192 in 74% as a white solid. Finally, boroxin
192 was reacted with citric acid in EtOAc to dissociate the
trimer, resulting in ixazomib citrate (XXIV) in 88% yield as a
crystalline solid.
Drug interactions
Potentially hazardous interactions with other drugs Antibacterials: concentration reduced by rifampicin - avoid. Antidepressants: concentration possibly reduced by St John’s wort - avoid. Antiepileptics: concentration possibly reduced by carbamazepine, fosphenytoin and phenytoin - avoid. Antipsychotics: increased risk of agranulocytosis with clozapine - avoid.
Metabolism
Ixazomib citrate is a prodrug that rapidly hydrolyses
under physiological conditions to its biologically active
form, ixazomib. Metabolism is by multiple CYP enzymes
and non-CYP proteins. At clinically relevant ixazomib
concentrations, in vitro studies using human cDNAexpressed cytochrome P450 isozymes indicate that no
specific CYP isozyme predominantly contributes to
ixazomib metabolism and non-CYP proteins contribute
to overall metabolism.
62% of the administered dose is excreted in urine and
22% in the faeces.
Check Digit Verification of cas no
The CAS Registry Mumber 1201902-80-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,1,9,0 and 2 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1201902-80:
(9*1)+(8*2)+(7*0)+(6*1)+(5*9)+(4*0)+(3*2)+(2*8)+(1*0)=98
98 % 10 = 8
So 1201902-80-8 is a valid CAS Registry Number.
1201902-80-8Relevant academic research and scientific papers
Synthetic process research of ixazomib
-
, (2019/11/04)
The invention discloses a synthesis method of ixazomib. The yield and the purity of a target product can be greatly increased with the method.
Boron-containing intermediate and application of same to medical industry
-
Paragraph 0059; 0060; 0061; 0062, (2017/08/28)
The invention discloses a preparation method for novel boron-containing intermediate I and a boron-containing drug MLN9708. The novel boron-containing intermediate I prepared by using a fluorination reagent is applied to preparation of the antitumor drug MLN9708; the intermediate has stable chemical properties in normal-temperature air, is easy to recrystallize and purify; and the intermediate and citric acid undergo a one-step reaction under the action of an alkaline reagent and a silicon reagent so as to prepare the antitumor drug MLN9708. The preparation method provided by the invention has no special requirements on production equipment, is mild in reaction conditions, uses commercially available raw materials and is suitable for industrial production.
BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF
-
Page/Page column 63, (2010/01/12)
The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
